U.S. flag

An official website of the United States government

GTR Home > Tests > Oncotype DX Breast Recurrence Score Assay


Test name


Oncotype DX Breast Recurrence Score Assay

Purpose of the test


This is a clinical test intended for Help: Predictive, Prognostic, Recurrence, Therapeutic management



Loading data ......

Click Indication tab for more information.

How to order


Order URL Help: https://precisiononcology.exactsciences.com/healthcare-providers/treatment-determination/breast-cancer/oncotype-dx-breast-recurrence-score/how-to-order

Specimen source

Paraffin block


Molecular Genetics
RRNA analysis
  • Other
  • None/not applicable

Summary of what is tested

Loading data ......

Click Methodology tab for more information.

Clinical utility


Guidance for management

Clinical validity


The Oncotype DX Breast Recurrence Score test result (the Recurrence Score value) has been significantly correlated with distant breast cancer recurrence, breast cancer-specific survival, disease-free-survival and overall survival. Several studies demonstrate the clinical utility of the Breast Recurrence Score for providing a comprehensive and individualized risk assessment for early-stage invasive breast cancer. More info on clinical validity, please visit: https://precisiononcology.exactsciences.com/healthcare-providers/treatment-determination/breast-cancer/oncotype-dx-breast-recurrence-score/clinical-evidence/clinical-overview. To see publications that detail analytical validity , please visit: https://www.exactsciences.com/publications/list?cancer_type=Breast%20Cancer&product_type=Product&product=Oncotype%20DX%20Breast%20Recurrence%20Score%C2%AE%20test


Not provided

Suggested reading

  • Cardoso et al., 2016
  • Ward et al., 2013
    Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis.

Clinical resources

Practice guidelines

  • NICE, 2024
    UK NICE Guideline NG101, Early and locally advanced breast cancer: diagnosis and management, 2024
  • NCCN, 2023
    Breast Cancer, NCCN Guidelines Version 4.2022
  • NCCN, 2022
    Breast Cancer Screening and Diagnosis, NCCN, Version 1.2022
  • NICE, 2018
    Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (DG34)
  • NICE, 2018
    Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer, NICE, 2018
  • NCCN, 2014
    National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Breast Cancer (See 2022 Update)
  • NICE, 2013
    DG10 Gene expression profiling and expanded immunohistochemistry tests for guiding adjuvant chemotherapy decisions in early breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostrat: information for the public
  • AHRQ, 2013
    Technology Assessment on Genetic Testing or Molecular Pathology Testing of Cancers with Unknown Primary Site to Determine Origin (ARCHIVED)
  • NCCN, 2011
    NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology.

Consumer resources

IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.